{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:11:03Z","timestamp":1779912663523,"version":"3.53.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T00:00:00Z","timestamp":1251331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T00:00:00Z","timestamp":1251331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1038\/leu.2009.168","type":"journal-article","created":{"date-parts":[[2009,8,27]],"date-time":"2009-08-27T10:30:42Z","timestamp":1251369042000},"page":"1957-1963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":168,"title":["Harmonization of molecular monitoring of CML therapy in Europe"],"prefix":"10.1038","volume":"23","author":[{"given":"M C","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C P","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Erben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Hanfstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Branford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,27]]},"reference":[{"key":"BFleu2009168_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 1990; 247: 824\u2013830.","journal-title":"Science"},{"key":"BFleu2009168_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561\u2013566.","journal-title":"Nat Med"},{"key":"BFleu2009168_CR3","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Chronic Myelogenous Leukemia, v.2.2010. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/cml.pdf (Last accessed 14 August 2009)."},{"key":"BFleu2009168_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809\u20131820.","journal-title":"Blood"},{"key":"BFleu2009168_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28\u201337.","journal-title":"Blood"},{"key":"BFleu2009168_CR6","doi-asserted-by":"crossref","unstructured":"Hughes T . ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring. Hematology Am Soc Hematol Educ Program 2006, 211\u2013218.","DOI":"10.1182\/asheducation-2006.1.211"},{"key":"BFleu2009168_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129\u2013141.","journal-title":"Cancer Cell"},{"key":"BFleu2009168_CR8","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Giles F, Bhalla KN, Larson RA, Gattermann N, Ottmann OG et al. Nilotinib in chronic myeloid leukemia patients in chronic phase with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study. Blood 2008; 112, Abstract 3238.","DOI":"10.1182\/blood.V112.11.3238.3238"},{"key":"BFleu2009168_CR9","doi-asserted-by":"crossref","unstructured":"Cortes J, O\u2019Brien S, Jones D, Ferrajoli A, Konopleva M, Borthakur G et al. Efficacy of nilotinib (formerly AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Blood 2008; 112, abstract 446.","DOI":"10.1182\/blood.V112.11.446.446"},{"key":"BFleu2009168_CR10","doi-asserted-by":"crossref","unstructured":"Rosti G, Castagnetti F, Poerio A, Breccia M, Levato L, Capucci A et al. High and early rates of cytogenetic and molecular response with nilotinib 800\u2009mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML working party. Blood 2008; 112, abstract 181.","DOI":"10.1182\/blood.V112.11.181.181"},{"key":"BFleu2009168_CR11","doi-asserted-by":"crossref","unstructured":"Baccarani M, Rosti G, Saglio G, Cortes J, Stone R, Niederwieser W et al. Dasatinib time to and durability of major and complete cytogenetic response in patients with chronic myeloid leukemia in chronic phase. Blood 2008; 112, abstract 450.","DOI":"10.1182\/blood.V112.11.450.450"},{"key":"BFleu2009168_CR12","doi-asserted-by":"crossref","unstructured":"Cortes J, O\u2019Brien S, Borthakur G, Jones D, Ravandi F, Koller C et al. Efficacy of dasatanib in patients with previously untreated chronic myelogenous leukemia in early chronic phase. Blood 2008; 112, abstract 182.","DOI":"10.1182\/blood.V112.11.182.182"},{"key":"BFleu2009168_CR13","doi-asserted-by":"crossref","unstructured":"Hochhaus A, M\u00fcller MC, Radich J, Branford S, Hanfstein B, Rousselot P et al. Dasatinib-associated major molecular responses are rapidly achieved in patients with chronic myeloid leukemia in chronic phase following resistance, suboptimal response or intolerance on imatinib. Blood 2008; 112, abstract 1095.","DOI":"10.1182\/blood.V112.11.1095.1095"},{"key":"BFleu2009168_CR14","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NCP, M\u00fcller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330\u20133338.","journal-title":"Blood"},{"key":"BFleu2009168_CR15","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423\u20131432.","journal-title":"N Engl J Med"},{"key":"BFleu2009168_CR16","doi-asserted-by":"crossref","unstructured":"Hughes TP, Hochhaus A, Branford S, M\u00fcller MC, Foroni L, Druker BJ et al. Reduction of BCR-ABL transcript levels at 6, 12, and 18 months correlates with long-term outcomes on imatinib at 72 mo: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in patients with chronic phase chronic myeloid leukemia. Blood 2008; 112, abstract 334.","DOI":"10.1182\/blood.V112.11.334.334"},{"key":"BFleu2009168_CR17","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu2009168_CR18","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-04-2139","volume":"11","author":"J Cortes","year":"2005","unstructured":"Cortes J, Talpaz M, O\u2019Brien S, Jones D, Luthra R, Shan J et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11: 3425\u20133432.","journal-title":"Clin Cancer Res"},{"key":"BFleu2009168_CR19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood.V95.1.62","volume":"95","author":"A Hochhaus","year":"2000","unstructured":"Hochhaus A, Reiter A, Sau\u00dfele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 2000; 95: 62\u201366.","journal-title":"Blood"},{"key":"BFleu2009168_CR20","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1038\/sj.leu.2401592","volume":"13","author":"JJ van Dongen","year":"1999","unstructured":"van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901\u20131928.","journal-title":"Leukemia"},{"key":"BFleu2009168_CR21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3324\/haematol.11172","volume":"92","author":"MC M\u00fcller","year":"2007","unstructured":"M\u00fcller MC, Saglio G, Lin F, Pfeifer H, Press RD, Tubbs RR et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica 2007; 92: 970\u2013973.","journal-title":"Haematologica"},{"key":"BFleu2009168_CR22","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2353\/jmoldx.2007.060134","volume":"9","author":"T Zhang","year":"2007","unstructured":"Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH, Kamel-Reid S . Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn 2007; 9: 421\u2013430.","journal-title":"J Mol Diagn"},{"key":"BFleu2009168_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/sj.leu.2404983","volume":"22","author":"MC M\u00fcller","year":"2008","unstructured":"M\u00fcller MC, Erben P, Saglio G, Gottardi E, Nyvold CG, Schenk T et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008; 22: 96\u2013102.","journal-title":"Leukemia"},{"key":"BFleu2009168_CR24","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/sj.leu.2404716","volume":"21","author":"J Saldanha","year":"2007","unstructured":"Saldanha J, Silvy M, Beaufils N, Arlinghaus R, Barbany G, Branford S et al. Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. Leukemia 2007; 21: 1481\u20131487.","journal-title":"Leukemia"},{"key":"BFleu2009168_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","volume":"20","author":"S Branford","year":"2006","unstructured":"Branford S, Cross NCP, Hochhaus A, Radich J, Saglio G, Kaeda J et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006; 20: 1925\u20131930.","journal-title":"Leukemia"},{"key":"BFleu2009168_CR26","volume-title":"Method Comparison and Bias Estimation Using Patient Samples: Approved Guideline Second-Edition (EP9-A2)","author":"J Krower","year":"2002","unstructured":"Krower J, Tholen D, Garber G, Goldschmidt H, Kroll M, Linnet K et al. Method Comparison and Bias Estimation Using Patient Samples: Approved Guideline Second-Edition (EP9-A2). The National Committee for Clinical Laboratory Standards: Wayne, PA, 22: 2002."},{"key":"BFleu2009168_CR27","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/sj.leu.2401566","volume":"13","author":"M Emig","year":"1999","unstructured":"Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825\u20131832.","journal-title":"Leukemia"},{"key":"BFleu2009168_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307\u2013310.","journal-title":"Lancet"},{"key":"BFleu2009168_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/096228029900800204","volume":"8","author":"JM Bland","year":"1999","unstructured":"Bland JM, Altman DG . Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8: 135\u2013160.","journal-title":"Stat Methods Med Res"},{"key":"BFleu2009168_CR30","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","volume":"17","author":"J Gabert","year":"2003","unstructured":"Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of \u2032real-time\u2032 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014a Europe Against Cancer program. Leukemia 2003; 17: 2318\u20132357.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2009168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2009168","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2009168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:27:47Z","timestamp":1648729667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2009168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,27]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["BFleu2009168"],"URL":"https:\/\/doi.org\/10.1038\/leu.2009.168","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,27]]},"assertion":[{"value":"29 June 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2009","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}